These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27882656)

  • 41. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
    Ota Y; Itoh Y; Kurohara T; Singh R; Elboray EE; Hu C; Zamani F; Mukherjee A; Takada Y; Yamashita Y; Morita M; Horinaka M; Sowa Y; Masuda M; Sakai T; Suzuki T
    ACS Med Chem Lett; 2022 Oct; 13(10):1568-1573. PubMed ID: 36262394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.
    Herrlinger EM; Hau M; Redhaber DM; Greve G; Willmann D; Steimle S; Müller M; Lübbert M; Miething CC; Schüle R; Jung M
    Chembiochem; 2020 Aug; 21(16):2329-2347. PubMed ID: 32227662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
    Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
    Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
    Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
    J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of lysine-specific demethylase 1 in ovarian endometriomas and its inhibition reduces cellular proliferation, cell cycle progression, and invasiveness.
    Ding D; Liu X; Guo SW
    Fertil Steril; 2014 Mar; 101(3):740-9. PubMed ID: 24388204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1.
    Wang B; Zhao B; Pang LP; Zhao YD; Guo Q; Wang JW; Zheng YC; Zhang XH; Liu Y; Liu GY; Guo WG; Wang C; Li ZH; Mao XJ; Yu B; Ma LY; Liu HM
    Pharmacol Res; 2017 Aug; 122():66-77. PubMed ID: 28571892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
    Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
    Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
    J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel dual-action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine-specific histone demethylase 1A inhibitor.
    Engel M; Gee YS; Cross D; Maccarone A; Heng B; Hulme A; Smith G; Guillemin GJ; Stringer BW; Hyland CJT; Ooi L
    J Neurochem; 2019 May; 149(4):535-550. PubMed ID: 30592774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
    Sakane C; Okitsu T; Wada A; Sagami H; Shidoji Y
    Biochem Biophys Res Commun; 2014 Jan; 444(1):24-9. PubMed ID: 24406160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
    Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
    Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
    Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
    Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
    Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.